AI Summary Terlivaz (terlipressin) is the FDA-approved vasoconstrictor for hepatorenal syndrome, usually given in the hospital through a vein together with albumin.
Medically reviewed.
Vasoconstrictor therapy is a group of medications that narrow blood vessels to treat hepatorenal syndrome (HRS), a serious loss of kidney function that can develop in people with advanced liver disease. By changing how blood flows through the abdomen, these medicines help send more blood to the kidneys and support kidney recovery. They are usually given together with albumin.
This page explains how vasoconstrictor therapy works, who may need it, and what to expect during treatment. It covers terlipressin (Terlivaz), midodrine (ProAmatine), and octreotide (Sandostatin). You can also connect with a liver specialist to discuss your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
VASOCONSTRICTOR THERAPY OVERVIEW
Vasoconstrictor therapy is a group of medications used to treat hepatorenal syndrome (HRS). In HRS, the kidneys stop working as they should because of advanced liver disease, not because of a disease of the kidneys themselves. Vasoconstrictors narrow blood vessels in the abdomen, which helps restore effective blood volume and sends more blood to the kidneys. Care usually combines a vasoconstrictor with albumin and close monitoring, and treatment plans depend on how sick a person is and what their care team decides.
You can explore the individual medicines below and learn how each one supports kidney function. Because the right choice depends on your diagnosis and health history, your healthcare team will decide which medicines fit your care plan.
Terlivaz is a vasoconstrictor given through a vein by healthcare professionals. It is an FDA-approved treatment for HRS and is commonly used with albumin. Treatment is usually short-term and takes place in a hospital.
Explore this therapy:
ProAmatine is an oral vasoconstrictor used off label, which means it is not FDA-approved for HRS but is used as part of combination therapy. It raises blood pressure and may improve blood flow to the kidneys. It is often used with albumin and octreotide.
Explore this therapy:
Sandostatin is a synthetic somatostatin analogue given as an injection under medical supervision. It reduces blood flow in the abdominal circulation and complements the effects of midodrine. It is also used for complications of portal hypertension.
Explore this therapy:
Providers may consider vasoconstrictor therapy for people with HRS or worsening kidney function related to cirrhosis, especially when they are hospitalized for complications of advanced liver disease. Some people also have low blood pressure from advanced liver disease and need extra circulatory support.
DIET & LIFESTYLE SUPPORT
Most people are treated in a hospital. After the kidneys stabilize, daily habits help protect your liver and kidneys and support the work of your medicines.
Strict avoidance of alcohol is part of long-term care after HRS treatment. It applies once you leave the hospital and stays in place as you continue to manage your advanced liver disease. Alcohol avoidance works alongside your medicines and follow-up visits as a core part of your care plan. If you find it hard to stay away from alcohol, tell your care team so they can help.
If you have ascites, which is a buildup of fluid in the abdomen, your team may ask you to follow a sodium-restricted diet. Follow any fluid recommendations your healthcare team gives you. If you are advised to, weigh yourself every day. Daily weight helps you and your team track your fluid status and notice changes early.
Take your liver disease medicines consistently, exactly as prescribed. Keep all follow-up visits with your hepatology team, who are the liver specialists managing your care. These visits include lab work to check your kidney function and blood pressure checks, which help your team see how you are doing and adjust your plan when needed.
HOW THE MEDICINES WORK
In advanced liver disease, blood vessels in the abdomen can widen, and less blood may reach the kidneys. Vasoconstrictor medicines narrow those vessels, raise effective blood volume, and improve kidney blood flow.
The medicines differ in how they are given and how long they are used. Your healthcare team chooses the approach based on your condition and whether you are in the hospital.
Terlipressin constricts blood vessels in the abdominal circulation, increases effective blood volume, and improves kidney blood flow. It is given through a vein by healthcare professionals, and treatment is usually short-term.
Midodrine is a tablet that narrows blood vessels and raises blood pressure. Octreotide is an injection that reduces blood flow in the abdominal circulation. They complement each other and are often used together with albumin.
Albumin is given through a vein to expand blood volume and improve circulation. It is commonly used with vasoconstrictors as part of HRS treatment.
Vasoconstrictor therapy is usually short-term. Terlivaz continues for up to 14 days, or until kidney function improves, side effects occur, or treatment is no longer helpful. Sandostatin is usually used for several days to weeks. ProAmatine is used short- to medium-term, and long-term use is uncommon. Your care team reassesses your treatment regularly.
TREATMENT MONITORING
Close monitoring helps your care team see how your kidneys respond and catch problems early. Depending on the medicine, monitoring may include kidney function, blood pressure, oxygen levels, and how well the treatment is working.
Kidney function is checked regularly. Response to terlipressin is typically assessed within the first few days of treatment.
Blood pressure is checked with all three medicines. Midodrine can raise blood pressure, so your team adjusts it carefully.
Oxygen levels and breathing are watched closely during terlipressin treatment. Tell your care team right away if you have trouble breathing.
Only a qualified healthcare provider can adjust your treatment plan based on your test results and health history.
COMMON QUESTIONS
Vasoconstrictor therapy treats hepatorenal syndrome (HRS), a loss of kidney function that can develop in people with advanced liver disease. The medicines narrow blood vessels in the abdomen, which increases effective blood volume and improves blood flow to the kidneys. Treatment usually includes albumin. Talk with your liver specialist about whether it fits your care plan.
These medicines narrow blood vessels, which raises effective blood volume and sends more blood to the kidneys. Terlipressin and midodrine constrict blood vessels, and midodrine also raises blood pressure. Octreotide reduces blood flow in the abdominal circulation and complements midodrine. Your healthcare provider can explain how this applies to your condition.
Providers consider this therapy for people with HRS or worsening kidney function related to cirrhosis, often while they are hospitalized for complications of advanced liver disease. Some people with low blood pressure from advanced liver disease may also need it. Only a qualified healthcare provider can decide which medicine is right for you.
Yes, albumin is commonly given with vasoconstrictors. It is an infusion that expands blood volume and improves circulation. Terlipressin is commonly used with albumin, and midodrine and octreotide are often combined with albumin as well.
Terlivaz (terlipressin) is FDA-approved for HRS. ProAmatine (midodrine) is used off label, meaning it is prescribed for a use the FDA has not formally approved, as part of combination therapy. Sandostatin (octreotide) is also used as part of combination therapy for HRS. Ask your provider why they chose a specific medicine for you.
Side effects differ by medicine. Terlivaz can cause abdominal pain, nausea, shortness of breath, high blood pressure, and reduced blood flow to the fingers or toes (peripheral ischemia). ProAmatine can cause high blood pressure, tingling, goosebumps, urinary retention, and headache. Sandostatin can cause nausea, abdominal pain, diarrhea, injection-site reactions, and changes in blood sugar. Your care team monitors you closely and can manage side effects.
Treatment length depends on the medicine and your response. Terlivaz is usually short-term and continues for up to 14 days, or until kidney function improves or treatment is no longer helpful. Sandostatin is usually used for several days to weeks. ProAmatine is used short- to medium-term, and long-term use is uncommon. Your team reassesses your treatment regularly.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
